Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $79.60 USD
Change Today +5.72 / 7.74%
Volume 15.0M
DGX On Other Exchanges
New York
As of 8:04 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

quest diagnostics inc (DGX) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/22/15 - $89.00
52 Week Low
10/15/14 - $56.27
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for QUEST DIAGNOSTICS INC (DGX)

quest diagnostics inc (DGX) Related Businessweek News

View More BusinessWeek News

quest diagnostics inc (DGX) Details

Quest Diagnostics Incorporated provides diagnostic testing information services in the United States and internationally. The company offers clinical testing services, such as routine testing, gene-based and esoteric testing, anatomic pathology services, and drugs-of-abuse testing, as well as related services and insights; laboratory testing services for new drugs, vaccines, and medical devices; analytic, on-site prevention, and wellness services; and risk assessment services for the life insurance industry. It also develops, manufactures, and markets diagnostic products, including Simplexa molecular chemistries for testing infectious disease and hospital-acquired infections; HerpeSelect HSV serology; and DxSelect IFA and ELISA products for testing infectious diseases. In addition, the company offers molecular diagnostic products in various segments, such as HIV-1 drug resistance testing under the ViroSeq brand name; and reproductive genetics and transplantation under the Atria and AlleleSeqr brand names. Further, it provides Care360 EHR, a solution that allows doctors to electronically create, manage, and distribute patient encounter notes, as well as for patient communication through a patient portal; and ChartMaxx, an enterprise content management system for hospitals. The company primarily offers its diagnostic information services under the Quest Diagnostics, AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Solstas, and Summit Health brands to patients, physicians, hospitals, accountable care organizations, integrated delivery networks, health plans, employers, and other customers through a network of laboratories, patient service centers, and phlebotomists in physician offices. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Madison, New Jersey.

45,000 Employees
Last Reported Date: 02/24/15
Founded in 1967

quest diagnostics inc (DGX) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $1.1M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $550.0K
Senior Vice President of Operations
Total Annual Compensation: $536.5K
Chief Medical Officer, Senior Vice President ...
Total Annual Compensation: $573.9K
Senior Vice President and Group Executive of ...
Total Annual Compensation: $534.6K
Compensation as of Fiscal Year 2014.

quest diagnostics inc (DGX) Key Developments

Quest Diagnostics Declares Quarterly Dividend Payable on July 22, 2015

Quest Diagnostics announced it will pay a quarterly dividend on its common stock of $0.38 per share on July 22, 2015 to shareholders of record on July 8, 2015.

Quest Diagnostics Launches QNatal Advanced

Quest Diagnostics launched QNatal Advanced, a noninvasive prenatal screening service for detecting chromosomal abnormalities in high-risk pregnancies. QNatal Advanced analyzes cell-free fetal DNA in circulating maternal blood to screen for common and rare chromosomal abnormalities, including those associated with trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome) and monosomy X (Turner syndrome), as well as fetal sex aneuploidies and select copy number variants. The screening test analyzes more chromosomal regions than most other noninvasive prenatal tests, and can be used as early as 10 weeks into gestation. With results of a QNatal Advanced screen, a woman and her physician may be better positioned to assess the appropriateness of invasive diagnostic testing, such as amniocentesis, which carries a slight risk of miscarriage, to confirm a finding.

Quest Diagnostics Announces LeukoVantage, Advancing Precision Medicine for Hematologic Malignancies

Quest Diagnostics announced LeukoVantage, an evidence-based genomic test service that aids in the diagnosis, prognosis, monitoring and selection of treatment for myeloid neoplasms, a group of hematologic malignancies that includes acute myeloid leukemia (AML), the most common form of adult acute leukemia, as well as myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPNs). For MDS, LeukoVantage may detect certain molecular markers to help identify early stages of the disease, complementing conventional diagnostic techniques. MDS is typically diagnosed through a series of tests that include complete blood count (CBC), morphology, and cytogenetic (chromosomal) analysis. For MPN, LeukoVantage may identify molecular markers that can aid the selection of certain targeted therapies, such as JAK2 inhibitors, and establishing a prognosis.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DGX:US $79.60 USD +5.72

DGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioMerieux €103.75 EUR +4.08
Hologic Inc $35.05 USD +0.09
Laboratory Corp of America Holdings $121.42 USD +1.06
QIAGEN NV €22.79 EUR +0.291
Roper Technologies Inc $177.15 USD -0.05
View Industry Companies

Industry Analysis


Industry Average

Valuation DGX Industry Range
Price/Earnings 22.8x
Price/Sales 1.5x
Price/Book 2.7x
Price/Cash Flow 18.9x
TEV/Sales 0.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUEST DIAGNOSTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at